Phase 4
Completed N=356
Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention
Source: ClinicalTrials.gov NCT02511236 ↗Enrolled (actual)
356
Serious AEs
1.1%
Results posted
Jun 2021
Primary outcomePrimary: The Number of Participants Reporting 7 Day Point Prevalence Abstinence — 54; 45 Participants
◆ Published Evidence
Emerging
14citations · ~2 / year
Reducing racial/ethnic tobacco cessation disparities via cognitive behavioral therapy: Design of a dualsite randomized controlled trial.
Summary
The purpose of this study is to test the effects of a group smoking cessation program. The study will also examine individual differences in response to the intervention program.
Linked Publications (2)
-
Reducing racial/ethnic tobacco cessation disparities via cognitive behavioral therapy: Design of a dualsite randomized controlled trial.
-
Cognitive behavioral therapy versus general health education for smoking cessation: A randomized controlled trial among diverse treatment seekers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number of Participants Reporting 7 Day Point Prevalence Abstinence |
54; 45 | — |
| PRIMARY Change in Perceived Stress Scores |
-1.47; -1.85 | — |
| PRIMARY Change in Depressive Symptoms Scores |
-1.84; -1.53 | — |
Eligibility Criteria
Inclusion Criteria
- Self-identify as African American/Black, Hispanic (any race), or White non-Hispanic
- Smoke at least 5 cigarettes/day or carbon monoxide (CO) reading of at least 8 ppm
- be over age 18
- speak/read English and/or Spanish
Exclusion Criteria
- Contraindications for transdermal nicotine patch therapy (TNP)
- Cognitive or mental health impairment that inhibits group treatment
- Currently being treated for smoking cessation, alcoholism, or illicit drug use
- Unable to attend sessions
- Indications that participant is not appropriate for the study (e.g., aggressive, intoxicated, disruptive, visibly ill)
- Does not self-identify as African American, Hispanic, or White (non-Hispanic)
Data sourced from ClinicalTrials.gov (NCT02511236) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.